Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
February 25, 2025 9:45 AM ESTRodman & Renshaw analyst Tony Butler reiterated a Buy rating and $33.00 price target on Bicycle Therapeutics (NASDAQ: BCYC)
The analyst comments "Bicycle Therapeutics plc (BCYC; Buy) provided its 4Q24 and FY2024 business updates this morning before the markets opened. Recall that Bicycles clinical pipeline consists of Bicycle-Toxin Conjugates (BTC) and Bicycle-radio conjugates (BRC) against solid tumors.... More
